Urapidil in the Treatment of Hypertension

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Urapidil is an α1-adrenoceptor antagonist which also has a central antihypertensive effect, the mechanism of which has yet to be conclusively defined. A number of open and comparative studies have produced evidence for the efficacy and safety of urapidil. A study recently completed by the author produced a dose-dependent antihypertensive effect of urapidil which, however, failed to achieve statistical significance, probably due to a large variance of the data and an unexpectedly large placebo effect. Adverse reactions are those expected from an α1blocker, particularly dizziness, as well as nausea and fatigue. Urapidil is potentially an important new antihypertensive agent; further variable dose and combination (with other antihypertensive agents) studies would help further define its therapeutic niche.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
Issue number6
StatePublished - Jun 1988
Externally publishedYes


Dive into the research topics of 'Urapidil in the Treatment of Hypertension'. Together they form a unique fingerprint.

Cite this